Moleculin reports pooled analysis shows no cardiotoxicity signal for Annamycin in five trials

Bitget2026/09/28 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Moleculin Biotech reported peer-reviewed results from a pooled analysis of five Annamycin trials published in Frontiers in Cardiovascular Medicine.
Findings were previously presented in clinical updates, now reinforced by journal publication and an independent Cleveland Clinic cardio-oncology review.
The analysis found no signs of treatment-related heart damage, supporting Annamycin’s positioning as a potentially safer anthracycline.
Data came from 90 patients in AML or metastatic soft tissue sarcoma, supporting continued development in the MIRACLE program for relapsed or refractory AML.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280700PRIMZONEFULLFEED9834355) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Moleculin reports pooled analysis shows no cardiotoxicity signal for Annamycin in five trials

You may also like

Crypto prices